| Dr Courtney Gray Wiese, MD | |
|
3850 S National Ave Ste 400, Springfield, MO 65807-5287 | |
| (417) 269-6850 | |
| (417) 269-5830 |
| Full Name | Dr Courtney Gray Wiese |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 13 Years |
| Location | 3850 S National Ave Ste 400, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366738155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | BP10040931 (Texas) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 2019004912 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Centers | Springfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lester E Cox Medical Centers | 5799787784 | 195 |
News Archive
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine have secured a $30.0 million financing commitment from Silicon Valley Bank's San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
The bodies of virtually all U.S. pregnant women carry multiple chemicals, including some banned since the 1970s and others used in common products such as non-stick cookware, processed foods and personal care products, according to a new study from UCSF. The study marks the first time that the number of chemicals to which pregnant women are exposed has been counted.
› Verified 8 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043386774 PECOS PAC ID: 5799787784 Enrollment ID: O20070213000014 |
News Archive
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine have secured a $30.0 million financing commitment from Silicon Valley Bank's San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
The bodies of virtually all U.S. pregnant women carry multiple chemicals, including some banned since the 1970s and others used in common products such as non-stick cookware, processed foods and personal care products, according to a new study from UCSF. The study marks the first time that the number of chemicals to which pregnant women are exposed has been counted.
› Verified 8 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902969272 PECOS PAC ID: 5799787784 Enrollment ID: O20070215000622 |
News Archive
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine have secured a $30.0 million financing commitment from Silicon Valley Bank's San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
The bodies of virtually all U.S. pregnant women carry multiple chemicals, including some banned since the 1970s and others used in common products such as non-stick cookware, processed foods and personal care products, according to a new study from UCSF. The study marks the first time that the number of chemicals to which pregnant women are exposed has been counted.
› Verified 8 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437543055 PECOS PAC ID: 5799787784 Enrollment ID: O20150701002605 |
News Archive
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine have secured a $30.0 million financing commitment from Silicon Valley Bank's San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
The bodies of virtually all U.S. pregnant women carry multiple chemicals, including some banned since the 1970s and others used in common products such as non-stick cookware, processed foods and personal care products, according to a new study from UCSF. The study marks the first time that the number of chemicals to which pregnant women are exposed has been counted.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Courtney Gray Wiese, MD Po Box 4046, Springfield, MO 65808-4046 Ph: (417) 269-5712 | Dr Courtney Gray Wiese, MD 3850 S National Ave Ste 400, Springfield, MO 65807-5287 Ph: (417) 269-6850 |
News Archive
Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine have secured a $30.0 million financing commitment from Silicon Valley Bank's San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
The bodies of virtually all U.S. pregnant women carry multiple chemicals, including some banned since the 1970s and others used in common products such as non-stick cookware, processed foods and personal care products, according to a new study from UCSF. The study marks the first time that the number of chemicals to which pregnant women are exposed has been counted.
› Verified 8 days ago
Dr. Michael P. Smith-o'brien, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1900 S National Ave, Suite 2970, Springfield, MO 65804 Phone: 417-820-3980 Fax: 417-820-3988 | |
Roy Robert Reid Iii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5407 E Riverview St, Springfield, MO 65809 Phone: 417-827-3911 | |
Dr. Staci Dawn Rogers, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3800 S National Ave Ste 700, Springfield, MO 65807 Phone: 417-269-8817 Fax: 417-269-8744 | |
Dr. Megan Christine Rooney Thompson, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3850 S National Ave Ste 400, Springfield, MO 65807 Phone: 417-269-6850 Fax: 417-269-5830 | |
Dr. Laird A. Bell, M.D., MPH Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1423 N Jefferson Ave, #b100, Springfield, MO 65802 Phone: 417-269-8825 Fax: 417-269-8744 | |
Dr. Thomas M. Shultz, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1000 E Primrose St, Suite 270, Springfield, MO 65807 Phone: 417-882-6900 Fax: 417-882-8912 | |
Dr. Andy J. Wright, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2828 N National Ave, Springfield, MO 65803 Phone: 417-837-4000 Fax: 417-875-4710 |